Multiple Ascending Dose Study of MHS552 in Adults With Type 1 Diabetes Mellitus

PHASE1WithdrawnINTERVENTIONAL

Timeline

Start Date

September 1, 2023

Primary Completion Date

April 14, 2025

Study Completion Date

April 14, 2025

Conditions

Type 1 Diabetes Mellitus

Interventions

DRUG

MHS552

MHS552 will be administered once weekly as subcutaneous injection for 4 (Part A) or 12 weeks (Part B)

DRUG

Placebo

Placebo will be administered once weekly as subcutaneous injection for 4 (Part A) or 12 weeks (Part B)